FDA approves Ampyra, the first MS drug to be taken orally that improves walking speed. It is also the first of its kind to receive FDA approval. Although Ampyra is appropriate for all types of MS, it is contraindicated for those MS patients with history of seizures or people with moderate to severe kidney disease.
***
Still under development are 2 other MS drugs that cut down the need for painful and time consuming injections or regular infusions.
The two tablets – Cladribine and Fingolimod – are expected to come to the market next year.
Cladribine seemed to markedly reduce the rates of relapse and also showed a slow down in progression of the associated disabilities. This tablet is to be taken 8-20 times a year.
Fingolimod lowered the relapse rates and also slowed the progression of related disabilities. It is recommended to take the tabs on a once daily dosing.
Although these studies bring a new light on the treatment of MS, there are still questions that need to be answered as to the safety and long-term results and risks.
Multiple sclerosis is a debilitating disorder which destroys the myelin sheath, the protective sheath covering the body’s central nervous system. Symptoms include extreme fatigue, difficulty walking, problems with memory and heat sensitivity.
This post is tagged ampyra, cladribine, fingolimod, multiple sclerosis
